Gayle M. Davey

Gayle M. Davey

Auto-generated profile, based on publicly available information

Gayle M. Davey

Department of Microbiology and Immunology, The University of Melbourne, Parkville, Victoria 3010, Australia

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2004 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
WHWilliam Ross Heath
William Ross Heath
GBGabrielle T. Belz
Gabrielle T. Belz
GBGeorg M. N. Behrens
Georg M. N. Behrens
CSChristopher M. Smith
Christopher M. Smith
SFSimon P. Forehan
Simon P. Forehan
JVJose A. Villadangos
Jose A. Villadangos

15 October 2008 in Blood
Verified
Journal Article
Open access
PDF file
ICIrina Caminschi
Irina Caminschi
APAnna I. Proietto
Anna I. Proietto
FAFatma Ahmet
Fatma Ahmet
SKSusie Kitsoulis
Susie Kitsoulis
JTJoo Shin Teh
Joo Shin Teh
MLMireille H. Lahoud
Mireille H. Lahoud
A novel dendritic cell (DC)–restricted molecule, Clec9A, was identified by gene expression profiling of mouse DC subtypes. Based on sequence similarity, a human ortholog was identified. Clec9A encodes a type II membrane protein with a single extracellular C-type lectin domain. Both the mouse Clec9A and human CLEC9A were cloned and expressed, and monoclonal antibodies (mAbs) against each were generated. Surface staining revealed that Clec9A was selective for mouse DCs and was restricted to the CD8+ conventional DC and plasmacytoid DC subtypes. A subset of human blood DCs also expressed CLEC9A. A single injection of mice with a mAb against Clec9A, which targets antigens (Ags) to the DCs, produced a striking enhancement of antibody responses in the absence of added adjuvants or danger signals, even in mice lacking Toll-like receptor signaling pathways. Such targeting also enhanced CD4 and CD8 T-cell responses. Thus, Clec9A serves as a new marker to distinguish subtypes of both mouse and human DCs. Furthermore, targeting Ags to DCs with antibodies to Clec9A is a promising strategy to enhance the efficiency of vaccines, even in the absence of adjuvants.

11 July 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PSPetra Schnorrer
Petra Schnorrer
GBGeorg M. N. Behrens
Georg M. N. Behrens
NWNicholas S. Wilson
Nicholas S. Wilson
JPJoanne L. Pooley
Joanne L. Pooley
CSChristopher M. Smith
Christopher M. Smith
JVJose A. Villadangos
Jose A. Villadangos
Mouse spleens contain three populations of conventional (CD11chigh) dendritic cells (DCs) that play distinct functions. The CD8+DC are unique in that they can present exogenous antigens on their MHC class I molecules, a process known as cross-presentation. It is unclear whether this special ability is because only the CD8+DC can capture the antigens used in cross-presentation assays, or because this is the only DC population that possesses specialized machinery for cross-presentation. To solve this important question we examined the splenic DC subsets for their ability to both present via MHC class II molecules and cross-present via MHC class I using four different forms of the model antigen ovalbumin (OVA). These forms include a cell-associated form, a soluble form, OVA expressed in bacteria, or OVA bound to latex beads. With the exception of bacterial antigen, which was poorly cross-presented by all DC, all antigenic forms were cross-presented much more efficiently by the CD8+DC. This pattern could not be attributed simply to a difference in antigen capture because all DC subsets presented the antigen via MHC class II. Indeed, direct assessments of endocytosis showed that CD8+and CD8−DC captured comparable amounts of soluble and bead-associated antigen, yet only the CD8+DC cross-presented these antigenic forms. Our results indicate that cross-presentation requires specialized machinery that is expressed by CD8+DC but largely absent from CD8−DC. This conclusion has important implications for the design of vaccination strategies based on antigen targeting to DC.

25 October 2010 in Journal of Experimental Medicine
Verified
Journal Article
Open access
HLHenning Lauterbach
Henning Lauterbach
BBBarbara Bathke
Barbara Bathke
SGStefanie Gilles
Stefanie Gilles
CTClaudia Traidl-Hoffmann
Claudia Traidl-Hoffmann
CLChristian A. Luber
Christian A. Luber
HHHubertus Hochrein
Hubertus Hochrein
Polyinosinic:polycytidylic acid (poly IC), a double-stranded RNA, is an effective adjuvant in vivo. IFN-λs (also termed IL-28/29) are potent immunomodulatory and antiviral cytokines. We demonstrate that poly IC injection in vivo induces large amounts of IFN-λ, which depended on hematopoietic cells and the presence of TLR3 (Toll-like receptor 3), IRF3 (IFN regulatory factor 3), IRF7, IFN-I receptor, Fms-related tyrosine kinase 3 ligand (FL), and IRF8 but not on MyD88 (myeloid differentiation factor 88), Rig-like helicases, or lymphocytes. Upon poly IC injection in vivo, the IFN-λ production by splenocytes segregated with cells phenotypically resembling CD8α+ conventional dendritic cells (DCs [cDCs]). In vitro experiments revealed that CD8α+ cDCs were the major producers of IFN-λ in response to poly IC, whereas both CD8α+ cDCs and plasmacytoid DCs produced large amounts of IFN-λ in response to HSV-1 or parapoxvirus. The nature of the stimulus and the cytokine milieu determined whether CD8α+ cDCs produced IFN-λ or IL-12p70. Human DCs expressing BDCA3 (CD141), which is considered to be the human counterpart of murine CD8α+ DCs, also produced large amounts of IFN-λ upon poly IC stimulation. Thus, IFN-λ production in response to poly IC is a novel function of mouse CD8α+ cDCs and their human equivalents.

15 July 2011 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
MLMireille H. Lahoud
Mireille H. Lahoud
FAFatma Ahmet
Fatma Ahmet
SKSusie Kitsoulis
Susie Kitsoulis
SWSoo San Wan
Soo San Wan
DVDavid Vremec
David Vremec
ICIrina Caminschi
Irina Caminschi
Three surface molecules of mouse CD8+ dendritic cells (DCs), also found on the equivalent human DC subpopulation, were compared as targets for Ab-mediated delivery of Ags, a developing strategy for vaccination. For the production of cytotoxic T cells, DEC-205 and Clec9A, but not Clec12A, were effective targets, although only in the presence of adjuvants. For Ab production, however, Clec9A excelled as a target, even in the absence of adjuvant. Potent humoral immunity was a result of the highly specific expression of Clec9A on DCs, which allowed longer residence of targeting Abs in the bloodstream, prolonged DC Ag presentation, and extended CD4 T cell proliferation, all of which drove highly efficient development of follicular helper T cells. Because Clec9A shows a similar expression pattern on human DCs, it has particular promise as a target for vaccines of human application.

23 September 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
RLRachel J. Lundie
Rachel J. Lundie
TKTania F. de Koning-Ward
Tania F. de Koning-Ward
GDGayle M. Davey
Gayle M. Davey
CNCatherine Q. Nie
Catherine Q. Nie
DHDiana S. Hansen
Diana S. Hansen
WHWilliam Ross Heath
William Ross Heath
Although CD8 + T cells do not contribute to protection against the blood stage of Plasmodium infection, there is mounting evidence that they are principal mediators of murine experimental cerebral malaria (ECM). At present, there is no direct evidence that the CD8 + T cells mediating ECM are parasite-specific or, for that matter, whether parasite-specific CD8 + T cells are generated in response to blood-stage infection. To resolve this and to define the cellular requirements for such priming, we generated transgenic P. berghei parasites expressing model T cell epitopes. This approach was necessary as MHC class I-restricted antigens to blood-stage infection have not been defined. Here, we show that blood-stage infection leads to parasite-specific CD8 + and CD4 + T cell responses. Furthermore, we show that P. berghei -expressed antigens are cross-presented by the CD8α + subset of dendritic cells (DC), and that this induces pathogen-specific cytotoxic T lymphocytes (CTL) capable of lysing cells presenting antigens expressed by blood-stage parasites. Finally, using three different experimental approaches, we provide evidence that CTL specific for parasite-expressed antigens contribute to ECM.